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Negative values are in favor of VMAT plans. *: difference is 
statistically significant (p<0.05). 
Conclusions: For the liver patients, the automatically 
generated dual-arc VMAT plans are substantially better than 
the manually generated non-coplanar CK plans, while 
requiring no workload. In addition, delivery times with VMAT 
are much shorter. 
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Purpose/Objective: A prospective observational study 
started in 2010 with the goal of developing predictive models 
of urinary (UR) toxicity (tox) and of erectile dysfunction after 
high dose radical radiotherapy (RT) for prostate cancer. Aim 
of this ad-interim analysis was to assess correlations between 
incidence of UR symptoms (symps) in the first 18 months 
(mos) after RT completion (as measured by the International 
Prostate Symptom Score, IPSS) and clinical/dosimetric risk 
factors.  
Materials and Methods: The trial included patients (pts) 
treated with conventional fractionation (74-80Gy at 1.8-
2Gy/fr) or moderate hypofractionation (65-75.2Gy at 2.2-
2.7Gy/fr), 5 fr/week. Prospectively collected clinical factors: 
T stage, comorbidities, drugs, androgen deprivation (AD), 
previous surgeries, smoking, alcohol, age, BMI. Bladder DVHs 
were corrected with alfa/beta=3Gy. IPSS was prospectively 
filled in at start/end of RT, at 3 and 6 mos follow-up (fup) 
and every 6 mos thereafter, till 5 yrs fup. We here 
considered an IPSS≥15 in the first 18 mos after RT completion 
as the UR tox endpoint (onset of moderate-severe UR symp), 
end RT IPSS was excluded, as relating to tox during RT. 
Analysis was accomplished for whole population and for 
subgroup with basal IPSS<15. A multivariate logistic 
regression (MVR) was performed. Choice of relevant factors 
to be included was carried out through an in-silico 
methodology combining bootstrap resampling, backward 
feature selection based on minimization of residuals and 
basket/network analysis of bootstrapped models. The 
features with the greatest % of occurrences (OCC) in the 
bootstrapped models were included in MVR. KNIME software 
was used. 
Results: By Nov 2014, 542 pts were enrolled. 
Clinical/dosimetric/endpoint data (18mos) available for 211 
pts, minimum fup 18mos. Incidence of IPSS≥15: 44/211 (21%) 
in the whole population and 34/193 (18%) in pts with basal 
IPSS<15. A 4-variable model was considered (AUC=0.81, CI 
0.75-0.86) including: basal IPSS (continuous variable, OR=1.2, 
OCC=98%), bladder volume receiving >78Gy (V78Gy, cont var, 
OR=1.09, OCC=69%), age (cont var, OR=1.05, OCC=34%) and 
diabetes (OR=2.7, OCC=20%). The model was confirmed for 
pts with basal IPSS<15 (AUC=0.79). 
Figure panel (a) shows %OCC of risk factors in 500 
simulations, while panel (b) reports rates of IPSS≥15 as a 
function of V78Gy. Minimizing V78Gy has a relevant impact 
on lowering toxicity incidence. ROC analysis suggests a cutoff 
V78Gy=6% (15% vs 34% UR tox below/above cutoff) 
 
Conclusions: Ad interim analysis shows an important 
correlation between UR tox at 18mos fup and bladder V78Gy, 
a cutoff V78Gy=6% can be suggested. Basal IPSS, age and 
diabetes act as modifiers of dose-response relationship (risk 
factors). Due to the timing of onset of late radioinduced UR 
toxicity (incidence increasing till 5yr fup), this interesting 
result has to be confirmed when longer fup will be available.  
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